D. E. Shaw & Co., Inc. Fate Therapeutics Inc Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 433,192 shares of FATE stock, worth $658,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares

433,192

Previous 1,536,633 71.81%

Holding current value

$658,451

Previous $2.54 Million 86.51%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.79 - $1.87 $871,718 - $2.06 Million	-1,103,441 Reduced 71.81%	433,192 $342,000
Q4 2024 Feb 14, 2025	SELL	$1.61 - $3.35 $2.96 Million - $6.17 Million	-1,841,017 Reduced 54.51%	1,536,633 $2.54 Million
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $2.18 Million - $3.9 Million	-700,272 Reduced 17.17%	3,377,650 $11.8 Million
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $4.39 Million - $9.54 Million	1,346,956 Added 49.32%	4,077,922 $13.4 Million
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $3.01 Million - $7.11 Million	-851,013 Reduced 23.76%	2,730,966 $20 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $1.86 Million - $4.45 Million	-1,129,685 Reduced 23.98%	3,581,979 $13.4 Million
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $226,694 - $565,614	112,225 Added 2.44%	4,711,664 $9.99 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $7.78 Million - $10.8 Million	1,634,197 Added 55.11%	4,599,439 $21.9 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $11.5 Million - $30.1 Million	2,707,319 Added 1049.66%	2,965,242 $16.9 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $2.54 Million - $6.15 Million	257,923 New	257,923 $2.6 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $852,556 - $1.15 Million	-17,821 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $3.9 Million - $6.29 Million	-65,727 Reduced 78.67%	17,821 $1.06 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $15 Million - $20.6 Million	-222,690 Reduced 72.72%	83,548 $7.25 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $6.49 Million - $10.6 Million	-89,919 Reduced 22.7%	306,238 $25.2 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $4.96 Million - $13.1 Million	-130,170 Reduced 24.73%	396,157 $36 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $2.29 Million - $3.05 Million	75,367 Added 16.71%	526,327 $21 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $601,429 - $1.05 Million	29,759 Added 7.07%	450,960 $15.5 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $5.44 Million - $10 Million	314,949 Added 296.42%	421,201 $9.36 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $1.42 Million - $2.2 Million	106,252 New	106,252 $2.08 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $206,091 - $299,745	-13,322 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $207,956 - $272,301	13,322 New	13,322 $270,000
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $337,051 - $496,010	-36,796 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $231,814 - $506,680	36,796 New	36,796 $359,000

Others Institutions Holding FATE

# of Institutions

144

Shares Held

97M

Call Options Held

56.7K

Put Options Held

5.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $147M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account